Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

BACKGROUND AND AIM: The aim of prospective study was to determine the prognostic value of combined measures of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and pentraxin 3 (PTX3) according to the culprit-plaque morphology (plaque rupture versus plaque erosion) in relation to the in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaoxiao, Song, Li, Wang, Ying, Li, Jiannan, Zhou, Jinying, Chen, Runzhen, Liu, Chen, Zhou, Peng, Sheng, Zhaoxue, Chen, Yi, Zhao, Hanjun, Yan, Hongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524062/
https://www.ncbi.nlm.nih.gov/pubmed/34703271
http://dx.doi.org/10.2147/JIR.S334246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524062/
https://www.ncbi.nlm.nih.gov/pubmed/34703271
http://dx.doi.org/10.2147/JIR.S334246

Ejemplares similares